Table 1 Descriptive data at baseline (T0) for 950 patients and at 5-year follow up (T5) in 726 of the patients diagnosed with early rheumatoid arthritis
From: Co-morbidity in patients with early rheumatoid arthritis - inflammation matters
Characteristics | Values |
|---|---|
Age at onset of symptoms, years | 55.6 (14.4) |
Female/male, T0 | 649/301 (68.3/31.7) |
Duration of symptoms at T0, months | 6.7 (3.5) |
RF+ | 75.3 |
ANA+ | 22.0 |
ACPA+ | 69.0 |
HLA-SE+ | 58.0 |
Disease activity and severity at T0 | |
ESR, mm/h | 30.1 (23.2) |
CRP, mg/L | 20.7 (24.3) |
HAQ | 0.86 (0.6) |
Tender joint count | 6.4 (5.7) |
Swollen joint count | 7.0 (5.2) |
VAS pain, mm | 43.4 (25.7) |
VAS global, mm | 44.4 (25.7) |
AUC DAS28, 6 months | 25.1 (7.2) |
AUC DAS28, 12 months | 46.2 (13.4) |
AUC DAS28, 24 months | 86.5 (25.6) |
Ex-RA ≤ T5 | 4.9 |
Nodules ≤ T5 | 16.4 |
Smoking ever, T0 | 65.8 |
Treatments | |
DMARDs within 3 months after T0 | 90.1 |
DMARDs ever ≤ T5 | 97.8 |
Methotrexate ever ≤ T5 | 86.9 |
Biological treatment ever ≤ T5 | 16.5 |
Time without DMARDs from symptom onset, months | 6.8 (4.9) |
Time without DMARDs T0–T5, months | 8.4 (15.7) |
NSAIDs ever ≤ T5 | 84.0 |
Cox-2 inhibitors ever ≤ T5 | 26.5 |
Corticosteroids T0–T5, months | 22.2 (23.8) |
Corticosteroids ever ≤ T5 | 71.0 |